10-Q/A: Avenir Wellness Solutions Restates Q1 2022 Earnings Due to Share Calculation Error

Avenir Wellness Solutions has filed an amended quarterly report to correct an error in the calculation of weighted average shares outstanding, impacting earnings per share for the first quarter of 2022.

Summary

• Avenir Wellness Solutions, formerly known as CURE Pharmaceutical Holding Corp., has restated its first-quarter 2022 financial results due to an error in calculating weighted average shares outstanding.
• The restatement corrects the basic and diluted net loss per share to $0.07, from the previously reported $0.10.
• The company's Q1 2022 revenue was $1.1 million, down from $1.4 million in Q1 2021, primarily due to a decrease in direct-to-consumer sales.
• The company reported a net loss of $5.15 million for the quarter, compared to a net loss of $3.17 million in the same period last year.
• A significant impairment of goodwill of $2.7 million was recorded in Q1 2022, impacting the overall financial results.
• The company's operating activities consumed the majority of its cash resources, and it had a working capital deficit of approximately $22.8 million as of March 31, 2022.
• The company is exploring various financing alternatives to meet its working capital requirements.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including a restatement, revenue decline, increased net loss, goodwill impairment, and a substantial working capital deficit. While the company is seeking financing, the overall tone is negative due to the severity of the financial issues and the identified material weakness in internal controls.

Positives

• The company is actively seeking additional funding to sustain operations.
• The company has a diversified business model with revenue streams from pharmaceuticals, cannabinoids, and wellness products.
• The company has a state-of-the-art cGMP manufacturing facility.
• The company has a strong intellectual property portfolio with issued and pending patents.

Negatives

• The company experienced a decrease in revenue in Q1 2022 compared to Q1 2021.
• The company recorded a significant net loss of $5.15 million in Q1 2022.
• The company recorded a $2.7 million impairment of goodwill in Q1 2022.
• The company has a substantial working capital deficit of approximately $22.8 million.
• The company has identified a material weakness in its internal control over financial reporting related to segregation of duties.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing and achieving profitable operations.
• The company faces competition from larger pharmaceutical and wellness companies.
• The company's research and development activities involve the use of hazardous materials and chemicals, which are subject to environmental regulations.
• The company's financial results are subject to the impact of the COVID-19 pandemic.
• The company is subject to risks associated with litigation and regulatory matters.

Future Outlook

The company anticipates continuing to incur operating losses and negative cash flows from operations, at least into the near future, as it executes its commercialization and development plans. The company is currently discussing various financing alternatives with potential investors and believes these funds will be sufficient to meet the company's working capital requirements during the coming year.

Management Comments

• The company's management is focused on developing and manufacturing products that address unmet medical needs and create value to patients at competitive price points.
• Management is committed to maintaining a strong internal control environment and believes that remediation efforts will represent significant improvements in the control environment.

Industry Context

The company operates in the biopharmaceutical and wellness industries, which are characterized by high R&D expenditures, regulatory hurdles, and competition. The company's focus on novel drug delivery technologies and alternative dosage forms aligns with industry trends aimed at improving drug safety, efficacy, and patient adherence.

Comparison to Industry Standards

• The company's revenue decline in Q1 2022 is concerning, as many companies in the wellness and pharmaceutical sectors are experiencing growth.
• The significant net loss and goodwill impairment suggest potential challenges in the company's business model and asset valuation.
• The company's working capital deficit is substantial and requires immediate attention, as many companies in the sector maintain a positive working capital position.
• The identified material weakness in internal controls is a serious issue that needs to be addressed promptly to ensure the reliability of financial reporting.
• Compared to companies like Aquestive Therapeutics and BioDelivery Sciences International, which also focus on drug delivery, Avenir Wellness Solutions appears to be facing more significant financial and operational challenges.

Legal Proceedings

• On April 12, 2022, the Company filed a civil action in the California Super Court for the County of Ventura against an investor, alleging violations of California law.

Related Party Transactions

• The company has several related party transactions, including promissory notes with officers and affiliated investment companies.

Stakeholder Impact

• Shareholders are negatively impacted by the restatement, net loss, and goodwill impairment.
• Employees may be impacted by the company's financial challenges and potential restructuring.
• Customers may be impacted by potential changes in product availability or pricing.
• Creditors are at risk due to the company's substantial working capital deficit and reliance on debt financing.

Next Steps

• The company will continue to seek additional financing to meet its working capital requirements.
• The company will continue to implement measures to remediate the material weakness in its internal control over financial reporting.
• The company will continue to execute its commercialization and development plans.
• The company will continue to monitor and evaluate the effectiveness of its internal controls and procedures over financial reporting.

Key Dates

Keywords

restatement, earnings per share, weighted average shares, goodwill impairment, financial results, biopharmaceutical, drug delivery, oral thin film, wellness products, cGMP manufacturing, Sera Labs, financing, working capital, intellectual property, patents